Literature DB >> 20181913

Coamplification of HIV-1 proviral DNA and viral RNA in assays used for quantification of HIV-1 RNA.

H Wan1, A Seth, L Rainen, H Fernandes.   

Abstract

Elevated HIV-1 viral load (VL) observed in specimens frozen in situ in plasma preparation tubes (PPTs) compared to EDTA plasma specimens may affect therapeutic monitoring of HIV-infected patients. The increase in viral load is cell associated and minimized when plasma from the PPT is aspirated or recentrifuged prior to freezing. This study investigates the contribution of integrated HIV-1 proviral DNA to elevated VL in the quantification of HIV-1 RNA in plasma. Fifty paired specimens collected in EDTA tubes and PPTs frozen in situ were used for analysis. HIV-1 VL was measured using the COBAS Amplicor Monitor ultrasensitive test version 1.5. Contaminating proviral DNA was detected using a nested PCR targeting the Alu repeat in human genomic DNA and HIV pol gene simultaneously. Treatment of the specimen with DNase resulted in significantly lower quantifiable HIV-1 RNA in specimens from PPTs compared to the corresponding EDTA tubes (P = 0.004). After the RNA was destroyed by heat treatment, the mean HIV-1 RNA VL decreased by 79% in the EDTA tube compared to 65% in the PPT. The nested PCR amplified integrated proviral DNA in nucleic acid extracted from plasma in PPT and EDTA specimens with high viral load values. Likewise, a semiquantitative densitometric analysis revealed that the total amount of genomic DNA in the PPT was higher than that in the EDTA tube. Our investigation clearly shows that both proviral DNA and intracellular RNA are amplified simultaneously in the COBAS Amplicor HIV-1 Monitor assay and that proviral DNA contributes to the elevated VL in plasma frozen in PPTs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20181913      PMCID: PMC2884470          DOI: 10.1128/JCM.02034-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Increased levels of HIV RNA detected in samples with viral loads close to the detection limit collected in Plasma Preparation Tubes (PPT).

Authors:  Brigitte P Griffith; Donald R Mayo
Journal:  J Clin Virol       Date:  2005-10-25       Impact factor: 3.168

2.  HIV-1 viral load blips are of limited clinical significance.

Authors:  Patricia K Lee; Tara L Kieffer; Robert F Siliciano; Richard E Nettles
Journal:  J Antimicrob Chemother       Date:  2006-03-13       Impact factor: 5.790

3.  Update on HIV-1 viral load blips.

Authors:  Richard E Nettles; Tara L Kieffer
Journal:  Curr Opin HIV AIDS       Date:  2006-03       Impact factor: 4.283

4.  Evaluation of the VACUTAINER PPT Plasma Preparation Tube for use with the Bayer VERSANT assay for quantification of human immunodeficiency virus type 1 RNA.

Authors:  Tarek Elbeik; Patricia Nassos; Patricia Kipnis; Barbara Haller; Valerie L Ng
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

5.  In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA.

Authors:  Mark Sharkey; Karine Triques; Daniel R Kuritzkes; Mario Stevenson
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Transient viremia in HIV-infected patients and use of plasma preparation tubes.

Authors:  Valentina Stosor; Frank J Palella; Baiba Berzins; Michele Till; Angel Leake; Joan S Chmiel; Robert L Murphy
Journal:  Clin Infect Dis       Date:  2005-10-21       Impact factor: 9.079

7.  Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

Authors:  Kathleen Squires; Adriano Lazzarin; José M Gatell; William G Powderly; Vadim Pokrovskiy; Jean-François Delfraissy; Joseph Jemsek; Antonio Rivero; Willy Rozenbaum; Shannon Schrader; Michael Sension; Asda Vibhagool; Alexandra Thiry; Michael Giordano
Journal:  J Acquir Immune Defic Syndr       Date:  2004-08-15       Impact factor: 3.731

8.  Overestimation of human immunodeficiency virus type 1 load caused by the presence of cells in plasma from plasma preparation tubes.

Authors:  Anne-Marte Bakken Kran; Tom Øystein Jonassen; Mette Sannes; Kirsti Jakobsen; Andreas Lind; Arild Maeland; Mona Holberg-Petersen
Journal:  J Clin Microbiol       Date:  2009-05-06       Impact factor: 5.948

9.  Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures.

Authors:  Peter F Rebeiro; Asghar Kheshti; Sally S Bebawy; Samuel E Stinnette; Husamettin Erdem; Yi-Wei Tang; Timothy R Sterling; Stephen P Raffanti; Richard T D'Aquila
Journal:  Clin Infect Dis       Date:  2008-11-15       Impact factor: 9.079

10.  Elevation of viral load by PCR and use of plasma preparation tubes for quantification of human immunodeficiency virus type 1.

Authors:  S García-Bujalance; C Ladrón de Guevara; J González-García; J R Arribas; F Zamora; A Gutiérrez
Journal:  J Microbiol Methods       Date:  2007-02-07       Impact factor: 2.363

View more
  7 in total

Review 1.  Quality assurance of RNA expression profiling in clinical laboratories.

Authors:  Weihua Tang; Zhiyuan Hu; Hind Muallem; Margaret L Gulley
Journal:  J Mol Diagn       Date:  2011-10-20       Impact factor: 5.568

2.  Evaluation of effect of specimen-handling parameters for plasma preparation tubes on viral load measurements obtained by using the Abbott RealTime HIV-1 load assay.

Authors:  Helen Fernandes; Svetlana Morosyuk; Klara Abravaya; Madhuri Ramanathan; Lynne Rainen
Journal:  J Clin Microbiol       Date:  2010-05-19       Impact factor: 5.948

3.  Limited utility of dried-blood- and plasma spot-based screening for antiretroviral treatment failure with Cobas Ampliprep/TaqMan HIV-1 version 2.0.

Authors:  Souleymane Sawadogo; Andreas Shiningavamwe; Joy Chang; Andrew D Maher; Guoqing Zhang; Chunfu Yang; Esegiel Gaeb; Harold Kaura; Dennis Ellenberger; David W Lowrance
Journal:  J Clin Microbiol       Date:  2014-08-20       Impact factor: 5.948

4.  Successful use of Plasma Preparation Tubes™ (PPTs) in the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 test.

Authors:  Colleen S Kraft; José Nilo G Binongo; Eileen M Burd; Molly E Eaton; Cindy B McCloskey; Helen Fernandes; Charles E Hill; Angela M Caliendo
Journal:  J Clin Virol       Date:  2013-01-16       Impact factor: 3.168

5.  Fangchinoline inhibits human immunodeficiency virus type 1 replication by interfering with gp160 proteolytic processing.

Authors:  Zhitao Wan; Yimei Lu; Qingjiao Liao; Yang Wu; Xulin Chen
Journal:  PLoS One       Date:  2012-06-13       Impact factor: 3.240

6.  Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein.

Authors:  Zhitao Wan; Xulin Chen
Journal:  Retrovirology       Date:  2014-10-17       Impact factor: 4.602

7.  Systematic review of the accuracy of plasma preparation tubes for HIV viral load testing.

Authors:  Robert Luo; Jessica Markby; Jilian Sacks; Lara Vojnov
Journal:  PLoS One       Date:  2019-11-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.